Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ImmunoPrecise Antibodies Ltd. IPA
$3.34
+$0.52 (15.56%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
67076226.00000000
-
week52high
6.50
-
week52low
2.35
-
Revenue
19364000
-
P/E TTM
-3
-
Beta
0.55709300
-
EPS
-0.85000000
-
Last Dividend
0.00000000
-
Next Earnings Date
27 июл 2023 г. в 12:30
Описание компании
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Benchmark | Buy | 31 дек 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
ImmunoPrecise Antibodies Ltd. (IPA) Q2 2023 Earnings Call Transcript
Seeking Alpha
15 дек 2022 г. в 15:43
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q2 2023 Earnings Conference Call December 15, 2022 10:30 AM ET Company Participants Jennifer Bath – Chief Executive Officer Barry Duplantis – Vice President-Client Relations Ilse Roodink – Chief Scientific Officer Brad McConn – Chief Financial Officer Conference Call Participants Swayampakula Ramakanth – H.C.
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022
Business Wire
05 дек 2022 г. в 08:04
VICTORIA, British Columbia--( BUSINESS WIRE )--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2023, on Thursday, December 15, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.
ImmunoPrecise Antibodies Ltd. (IPA) Q1 2023 Earnings Call Transcript
Seeking Alpha
14 сент 2022 г. в 14:48
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q1 2023 Earnings Conference Call September 14, 2022 10:30 AM ET Company Participants Jennifer Bath - President & CEO Brad McConn - CFO Ilse Roodink - Chief Scientific Officer Barry Duplantis - VP, Client Relations Operator Good morning, and thank you for standing by.
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
Business Wire
08 сент 2022 г. в 09:03
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2023, on Wednesday, September 14, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise manag
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
Business Wire
26 июл 2022 г. в 08:04
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on Friday, July 29, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise man